On Sunday, December 3, CVS announced it had reached an agreement with Aetna for approximately US$69 billion.
The deal is one the year’s largest so far. It comes as insurers are under pressure to lower medical costs and retailers are under attack from new competitors, including an increasingly powerful Amazon. It creates the first health-care triple threat, combining CVS’s pharmacy and pharmacy benefit manager platform with Aetna’s insurance business.
According to the agreed terms, Aetna stockholders will receive US$207 per share, US$145 in cash and US$62 in stock, according to the source. An earlier report by Reuters, which first reported the terms, said Aetna’s board had already approved the deal.
Full Content: Washington Post
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google Faces DOJ Antitrust Trial, Publishers Watch Closely for Impact on Ad Market
Sep 9, 2024 by
CPI
India Moves to Challenge Big Tech Power in Digital Markets
Sep 9, 2024 by
CPI
US Tightens Grip on AI: New Reporting Rules for Developers and Cloud Providers
Sep 9, 2024 by
CPI
EU Court to Decide Apple’s €13bn Tax Battle
Sep 9, 2024 by
CPI
Google Lawyer Kevin Yingling Joins Freshfields Amid Antitrust Fight
Sep 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI